maribavir (Livtencity) Report issue

Small molecule Orphan Drug FDA Approved FDA First in Class Priority Review FDA
AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW
  • Now
Maribavir, sold under the brand name Livtencity, is an antiviral medication that is used to treat post-transplant cytomegalovirus (CMV). Maribavir is a cytomegalovirus pUL97 kinase inhibitor that works by preventing the activity of human cytomegalovirus enzyme pUL97, thus blocking virus replication.   Wikipedia

Chemistry

  • SMILES: CC(C)Nc1nc2cc(Cl)c(Cl)cc2n1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O
  • InChIKey: KJFBVJALEQWJBS-XUXIUFHCSA-N
  • Mol. Mass: 376.24
  • ALogP: 1.77
  • ChEMBL Molecule:
    maribavir  
More Chemistry

Pharmacology

Alternative names

1263w94 | 5,6-dichloro-2-isopropylamino-1-b-l-ribofuranosyl-1h-benzimidazole | benzimidavir | bw 1263w94 | bw-1263w94 | gw 1263 | gw-1263 | gw257406x | gw 257406x | gw-257406x | maribavir

Organizations (5)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (1)


 

Cytomegalovirus Infections (approved 2021)

Experimental Indications - Clinical Trial Phases 1-4 (4)


 

Cytomegalovirus Infections (Phase 4)

Healthy Volunteers (Phase 1)

HIV Infections (Phase 1)

Transplants (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 15
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue